---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-22-000020"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:34:27.080600+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q2 revenue down 44% to $2.86B; core revenue up 20%; EPS $7.47 GAAP, $9.77 non-GAAP

## Summary
- Excluding REGEN-COV, total revenue grew 20% to $2.849B, driven by EYLEA ($1.62B +14%) and Dupixent ($2.09B +40%).
- GAAP net income $852M ($7.47 diluted EPS) vs $3.099B ($27.97) Q2 2021; non-GAAP EPS $9.77 vs $25.80.
- Acquired Checkmate Pharmaceuticals for ~$250M and purchased Sanofi's Libtayo worldwide rights for $900M up-front.
- FDA approved Dupixent for atopic dermatitis in children 6 months-5 years and eosinophilic esophagitis; priority review for prurigo nodularis.
- Updated 2022 guidance: R&D $3.485-3.655B GAAP; SG&A $1.99-2.11B; gross margin on net product sales 90-91%.

## SEC filing metadata
- accession: 0001804220-22-000020
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422022000020/0001804220-22-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422022000020/regn-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-22-000020
- JSON: https://secwatch.observer/filing/0001804220-22-000020.json
- Plain text: https://secwatch.observer/filing/0001804220-22-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.